[go: up one dir, main page]

NO20061214L - 2,4-pyrimidindiaminer nyttige i behandling av neoplastiske sykdomme,r inflammatoriske forstyrrelser og immunsystemforstyrrelser - Google Patents

2,4-pyrimidindiaminer nyttige i behandling av neoplastiske sykdomme,r inflammatoriske forstyrrelser og immunsystemforstyrrelser

Info

Publication number
NO20061214L
NO20061214L NO20061214A NO20061214A NO20061214L NO 20061214 L NO20061214 L NO 20061214L NO 20061214 A NO20061214 A NO 20061214A NO 20061214 A NO20061214 A NO 20061214A NO 20061214 L NO20061214 L NO 20061214L
Authority
NO
Norway
Prior art keywords
disorders
pyrimidinediamines
useful
treatment
immune system
Prior art date
Application number
NO20061214A
Other languages
English (en)
Other versions
NO333306B1 (no
Inventor
Takanori Kanazawa
Naoko Matsuura
Osamu Ohmori
Ichiro Umemura
Eiji Kawahara
Keiichi Masuya
Takahiro Miyake
Nathanael Schiander Gray
Ruo Steensma
Greg Chopiuk
Jiqing Jiang
Yongqin Wan
Qiang Ding
Qiong Zhang
Donald Karanewsky
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34196260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061214(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0319227A external-priority patent/GB0319227D0/en
Priority claimed from GB0322370A external-priority patent/GB0322370D0/en
Application filed by Irm Llc filed Critical Irm Llc
Publication of NO20061214L publication Critical patent/NO20061214L/no
Publication of NO333306B1 publication Critical patent/NO333306B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Structural Engineering (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Nye pyrimidinderivater med formel (I) hvori R er valgt fra C6-10aryl, C5-10heteroaryl, C3-12cykloalkyl og C3-10heterocykloalkyl; R0-R6 er som beskrevet heri; og deres anvendelse for fremstilling av et medikament for behandling eller hindring av en sykdom som 5 responderer på inhibering av FAK og/eller ALK og/eller ZAP-70 og/eller IGF-IR.
NO20061214A 2003-08-15 2006-03-15 2,4-pyrimidindiaminer, farmasoytisk sammensetning og kombinasjon innbefattende en slik forbindelse samt anvendelse av forbindelsen NO333306B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0319227A GB0319227D0 (en) 2003-08-15 2003-08-15 Organic compounds
GB0322370A GB0322370D0 (en) 2003-09-24 2003-09-24 Organic compounds
PCT/EP2004/009099 WO2005016894A1 (en) 2003-08-15 2004-08-13 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Publications (2)

Publication Number Publication Date
NO20061214L true NO20061214L (no) 2006-05-15
NO333306B1 NO333306B1 (no) 2013-04-29

Family

ID=34196260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061214A NO333306B1 (no) 2003-08-15 2006-03-15 2,4-pyrimidindiaminer, farmasoytisk sammensetning og kombinasjon innbefattende en slik forbindelse samt anvendelse av forbindelsen

Country Status (31)

Country Link
US (2) US7893074B2 (no)
EP (2) EP2287156B1 (no)
JP (2) JP4607879B2 (no)
KR (1) KR100904570B1 (no)
AR (1) AR045458A1 (no)
AT (1) ATE542801T1 (no)
AU (2) AU2004264382A1 (no)
BR (2) BRPI0413616B8 (no)
CA (1) CA2533320A1 (no)
CO (1) CO5680434A2 (no)
CY (2) CY1112571T1 (no)
DK (2) DK2287156T3 (no)
EC (1) ECSP066371A (no)
ES (2) ES2380206T3 (no)
HR (2) HRP20120335T1 (no)
IL (1) IL173129A0 (no)
IS (1) IS2873B (no)
MA (1) MA27994A1 (no)
MX (1) MXPA06001759A (no)
MY (1) MY147449A (no)
NO (1) NO333306B1 (no)
NZ (1) NZ585188A (no)
PL (2) PL2287156T3 (no)
PT (2) PT1660458E (no)
RU (1) RU2395500C2 (no)
SG (1) SG145749A1 (no)
SI (2) SI1660458T1 (no)
TN (1) TNSN06052A1 (no)
TW (1) TWI378923B (no)
WO (1) WO2005016894A1 (no)
ZA (1) ZA200600464B (no)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2004313181A (ja) * 2003-04-02 2004-11-11 Canon Inc 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
US8131475B2 (en) * 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
PE20070362A1 (es) * 2005-07-15 2007-04-23 Glaxo Group Ltd COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
GB0517329D0 (en) * 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
KR101467723B1 (ko) * 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007085540A1 (en) * 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
WO2007120980A2 (en) 2006-02-17 2007-10-25 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2450437B1 (en) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP1914240B1 (en) 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
AR063527A1 (es) 2006-10-23 2009-01-28 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
HRP20141260T1 (xx) 2006-12-08 2015-03-13 Irm Llc Spojevi i sastavi kao inhibitori kinaze proteina
CN103641833A (zh) * 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EP2099771A1 (en) * 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
MX2009011090A (es) 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
KR20100042272A (ko) * 2007-07-16 2010-04-23 아스트라제네카 아베 피리미딘 유도체 934
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
CA2696824A1 (en) 2007-08-28 2009-03-12 Irm Llc Compounds and compositions as kinase inhibitors
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
CA2710118A1 (en) 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER
MX2010010968A (es) * 2008-04-07 2010-10-26 Irm Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
KR20170051521A (ko) 2008-04-16 2017-05-11 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA029131B1 (ru) * 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8569298B2 (en) * 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
RU2536584C2 (ru) * 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
SI2565193T1 (sl) 2009-01-23 2014-07-31 Rigel Pharmaceuticals, Inc. Sestavki in metode inhibicije JAK poti
ES2423804T3 (es) 2009-04-03 2013-09-24 Cellzome Gmbh Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2010142766A2 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
CN102498110A (zh) * 2009-06-10 2012-06-13 雅培制药有限公司 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
CA2763720A1 (en) * 2009-06-18 2010-12-23 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
EP2443106A1 (en) * 2009-06-18 2012-04-25 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
CA2771675A1 (en) * 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
US20130137709A1 (en) * 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
MX2012013274A (es) 2010-05-21 2013-05-28 Chemilia Ab Novedosos derivados de la pirimidina.
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
SG187796A1 (en) 2010-08-10 2013-03-28 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
TW201238938A (en) 2010-11-01 2012-10-01 Portola Pharm Inc Benzamides and nicotinamides as Syk modulators
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
RU2746159C2 (ru) * 2010-12-17 2021-04-08 Новартис Аг Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
JP2012153674A (ja) 2011-01-28 2012-08-16 Astellas Pharma Inc ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
EP2670401B1 (en) * 2011-02-02 2015-06-10 Novartis AG Methods of using alk inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
WO2012145569A1 (en) 2011-04-22 2012-10-26 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
JP6039683B2 (ja) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ， インコーポレイテッド ピラジンキナーゼ阻害剤
KR102068374B1 (ko) 2012-03-06 2020-01-20 세파론, 인코포레이티드 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
PT2825042T (pt) 2012-03-15 2018-11-16 Celgene Car Llc Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
RU2675850C2 (ru) * 2012-11-06 2018-12-25 Шанхай Фокон Фармасьютикал Ко Лтд Ингибиторы alk-киназы
CN103804299A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP2016520129A (ja) 2013-05-29 2016-07-11 セファロン、インク． Ａｌｋ阻害剤としてのピロロトリアジン
EP3010505A1 (en) 2013-06-18 2016-04-27 Novartis AG Pharmaceutical combinations
SG11201600055PA (en) * 2013-07-11 2016-02-26 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015038868A1 (en) * 2013-09-13 2015-03-19 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivatives
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3594359B1 (en) 2013-11-06 2022-05-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2015164604A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
CR20170146A (es) 2014-10-21 2017-08-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-yl)piperidin-1-il]pirimidina-2,4-diamina
WO2016100310A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
ES2994877T3 (en) 2015-07-24 2025-02-03 Celgene Corp Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106699743B (zh) * 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106883213B (zh) * 2015-12-15 2021-04-20 合肥中科普瑞昇生物医药科技有限公司 一种egfr和alk激酶的双重抑制剂
JP2019520382A (ja) * 2016-06-27 2019-07-18 杭州雷索薬業有限公司Ｈａｎｇｚｈｏｕ Ｒｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ ベンゾフランピラゾールアミン類プロテインキナーゼ阻害薬
AU2017319135B2 (en) 2016-08-29 2021-03-18 The Regents Of The University Of Michigan Aminopyrimidines as ALK inhibitors
KR101876514B1 (ko) 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
JP7085242B2 (ja) * 2017-12-21 2022-06-16 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのアリールホスフィンオキシド
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3863636A1 (en) 2018-10-08 2021-08-18 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
CN112771032B (zh) * 2018-10-29 2023-01-03 江苏先声药业有限公司 作为第四代egfr抑制剂的嘧啶吡唑类化合物
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US20220064196A1 (en) * 2019-01-17 2022-03-03 Betta Pharmaceuticals Co., Ltd. EGFR Inhibitors, Compositions and Methods Thereof
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
MX2021011209A (es) * 2019-03-15 2022-01-19 Massachusetts Gen Hospital Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
KR102168179B1 (ko) * 2019-10-31 2020-10-20 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
BR112022008535A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
US20210139517A1 (en) 2019-11-08 2021-05-13 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
JP7390487B2 (ja) * 2019-12-03 2023-12-01 サムジン ファーマシューティカル カンパニー，リミテッド 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3169286A1 (en) * 2020-02-25 2021-09-02 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of alk
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
JP2024502175A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのイソインドリノンアミノピリミジン化合物、その組成物及び使用
WO2022211573A1 (ko) * 2021-04-01 2022-10-06 주식회사 테라펙스 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
KR20240019071A (ko) 2021-04-02 2024-02-14 브릿지바이오테라퓨틱스(주) N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법
US20240382592A1 (en) 2021-04-09 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of anaplastic large cell lymphoma
CN118561952A (zh) 2021-05-05 2024-08-30 锐新医药公司 Ras抑制剂
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN119998298A (zh) 2022-06-10 2025-05-13 锐新医药公司 大环ras抑制剂
KR20240143136A (ko) 2023-03-23 2024-10-02 청주대학교 산학협력단 콘크리트 양생용 광발열 단열시트 및 콘크리트 구조물의 조기 시공 방법
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024251270A1 (zh) * 2023-06-08 2024-12-12 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129020C (no) 1964-12-15
US3432493A (en) * 1966-06-27 1969-03-11 Abbott Lab Substituted sulfanilamides
SU194829A1 (ru) * 1966-07-08 1967-04-12 Замещенных 5,6-дигидропирроло-
US3367149A (en) * 1966-12-15 1968-02-06 Minnesota Mining & Mfg Radiant white light source
DE2861560D1 (en) * 1977-11-28 1982-03-04 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5964558A (ja) * 1982-09-30 1984-04-12 三菱電機株式会社 耐熱軟質複合体の製造法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
ATE342892T1 (de) * 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE60017898T2 (de) * 1999-06-09 2006-01-12 Yamanouchi Pharmaceutical Co., Ltd. Neuartige heterocyclische carboxamidderivate
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US6376770B1 (en) * 2000-02-28 2002-04-23 Douglas Hyde Quick connecting universal electrical box and wiring system
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
EP1406875B1 (en) * 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
DE60225709T2 (de) * 2001-11-01 2009-05-07 Janssen Pharmaceutica N.V. Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003209077A1 (en) * 2002-02-08 2003-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
CN1665789A (zh) * 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
MXPA05001096A (es) * 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2598404T3 (es) * 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
ATE433447T1 (de) * 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DE602004008303T2 (de) * 2003-07-16 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
EP1781659B1 (en) * 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
US20050113398A1 (en) * 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
MXPA06003054A (es) * 2003-09-18 2006-05-31 Novartis Ag 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
AU2004264382A1 (en) 2005-02-24
HRP20120335T1 (hr) 2012-05-31
DK1660458T3 (da) 2012-05-07
BRPI0413616A (pt) 2006-10-17
JP4607879B2 (ja) 2011-01-05
IL173129A0 (en) 2006-06-11
EP2287156B1 (en) 2013-05-29
ZA200600464B (en) 2006-12-27
EP2287156A1 (en) 2011-02-23
SI1660458T1 (sl) 2012-05-31
DK2287156T3 (da) 2013-08-26
ATE542801T1 (de) 2012-02-15
BRPI0413616B8 (pt) 2021-05-25
CY1112571T1 (el) 2016-02-10
MA27994A1 (fr) 2006-07-03
EP1660458B1 (en) 2012-01-25
JP2007502260A (ja) 2007-02-08
KR100904570B1 (ko) 2009-06-25
US20110098280A1 (en) 2011-04-28
EP1660458A1 (en) 2006-05-31
MY147449A (en) 2012-12-14
CO5680434A2 (es) 2006-09-29
SI2287156T1 (sl) 2013-09-30
BRPI0413616B1 (pt) 2020-04-28
CA2533320A1 (en) 2006-02-24
US20080132504A1 (en) 2008-06-05
HK1091813A1 (en) 2007-01-26
ES2380206T3 (es) 2012-05-09
PT1660458E (pt) 2012-04-27
SG145749A1 (en) 2008-09-29
IS8349A (is) 2006-03-13
HRP20130724T1 (hr) 2013-10-11
AU2008229685A1 (en) 2008-10-30
PT2287156E (pt) 2013-08-26
RU2395500C2 (ru) 2010-07-27
TNSN06052A1 (en) 2007-10-03
CY1117015T1 (el) 2017-04-05
PL2287156T3 (pl) 2013-11-29
KR20060039938A (ko) 2006-05-09
TW200526598A (en) 2005-08-16
WO2005016894A1 (en) 2005-02-24
TWI378923B (en) 2012-12-11
ECSP066371A (es) 2006-08-30
BR122019017579B1 (pt) 2020-08-11
IS2873B (is) 2014-03-15
ES2424881T3 (es) 2013-10-09
NO333306B1 (no) 2013-04-29
RU2006107785A (ru) 2007-09-20
MXPA06001759A (es) 2006-05-12
PL1660458T3 (pl) 2012-07-31
US7893074B2 (en) 2011-02-22
NZ585188A (en) 2011-09-30
AR045458A1 (es) 2005-10-26
AU2008229685B2 (en) 2011-07-28
JP2010241830A (ja) 2010-10-28
BR122019017579B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
NO20061214L (no) 2,4-pyrimidindiaminer nyttige i behandling av neoplastiske sykdomme,r inflammatoriske forstyrrelser og immunsystemforstyrrelser
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20054726L (no) 2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
NO20073465L (no) Benzotiazol-derivater
NO20070981L (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon.
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20060168L (no) Pyridinylkarbamater som hormonsensitive lipaseinhibitorer
TNSN04165A1 (en) Substituted hydroxyethylamines
NO20051962L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
JO2282B1 (en) Oxazole derivatives
ATE369353T1 (de) Medizinisch verwendbare arylethanolamin verbindungen
NO20052739L (no) CCR5-antagonister som medikamenter
NO20062370L (no) Amidderivater
NO20050828L (no) lndol-3-svovelderivater
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
NO331002B1 (no) Tioxantinderivater og farmasoytiske preparater med tioxantinderivater
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS AS, CH